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In the present study, low dose treatment with betamethasone acetate alone achieved more 44 
consistent functional maturation of the preterm ovine lung compared to combined 45 
betamethasone acetate and betamethasone phosphate treatment, but without causing a 46 
significant reduction in fetal growth. We concluded that the elevated materno-fetal 47 
betamethasone concentration derived from the inclusion of betamethasone phosphate in 48 
antenatal corticosteroid therapy is likely redundant for fetal lung maturation, and may increase 49 
the risk of harm. 50 
 51 
[SHORT TITLE] 52 
The inclusion of betamethasone phosphate in ACS therapy was associated with increased 53 
treatment variability, lower birth weights, and did not improve lung maturation relative to use 54 
of betamethasone acetate alone. 55 
 56 
[AJOG AT A GLANCE] 57 
A. Why was this study conducted? 58 
Antenatal corticosteroid (ACS) therapy is widely used to improve preterm outcomes, with the 59 
primary beneficial effect being precocious maturation of the fetal lung. Although in clinical 60 
use for over 50 years, dosing is poorly optimized and adverse effects remain of concern. We 61 
and others have previously suggested that the materno-fetal steroid exposures achieved with 62 
current clinical dosing are excessive and may increase the risk of harm. Using a sheep model 63 








acetate when administered individually, and in combination with betamethasone phosphate as 65 
is widely used today.  66 
 67 
B. What are the key findings? 68 
We demonstrated that two doses of 0.125 mg/kg betamethasone acetate were associated with 69 
fetal lung maturation at least as effective as a standard clinical course of two 0.25 mg/kg doses 70 
of betamethasone phosphate + acetate. Surfactant protein A expression was strongly correlated 71 
with functional maturation of the fetal lung. The ACS therapy response rate was significantly 72 
higher in the low dose betamethasone acetate-only group compared to higher dose combined 73 
betamethasone phosphate + acetate group. Maternal and cord plasma betamethasone levels 74 
were significantly higher in the combined treatment group, the elevation of which were 75 
associated with lower birth weight and a greater degree of HPA axis perturbation, consistent 76 
with the established dose-dependent response to antenatal steroids. 77 
 78 
C. What does this study add to what is already known? 79 
We and others have demonstrated that functional lung maturation can be achieved at exposures 80 
significantly lower than those derived from current clinical dosing protocols. This report 81 
demonstrates betamethasone phosphate is redundant when used in combination with 82 
betamethasone acetate to precociously mature the preterm lung. Our data suggest that the 83 
elevated fetal betamethasone levels deriving from use of betamethasone phosphate are 84 
associated with a greater risk of lower birth weight and a greater degree of HPA axis 85 
perturbation. Critically, these data also suggest that combining betamethasone phosphate with 86 
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Background: Antenatal corticosteroid (ACS) therapy is standard of care for women at 93 
imminent risk of preterm labour. Despite this, much remains to be understood regarding an 94 
optimal (maximum benefit, minimal risk of side effects) ACS dosing strategy. Although 95 
conveying overall benefit when given to the right patient at the right time, ACS treatment 96 
efficacy is highly variable, and is not risk-free. Building on earlier findings, we hypothesized 97 
that when administered in combination with slow-release betamethasone acetate, 98 
betamethasone phosphate and the high materno-fetal betamethasone concentrations it 99 
generates are redundant for fetal lung maturation. 100 
Objective: Using an established sheep model of prematurity and post-natal ventilation of the 101 
preterm lamb, we aimed to compare the pharmacodynamic effects of a low-dose treatment with 102 
betamethasone acetate only against a standard dose of betamethasone phosphate and 103 
betamethasone acetate as recommended by the American College of Obstetricians and 104 
Gynaecologists for women at risk of imminent preterm delivery between 24 and 35+6 weeks’ 105 
gestation.  106 
Methods: Ewes carrying a single fetus at 122±1 d gestational age (term=150d) were 107 
randomized to receive either: i) maternal intramuscular injections of sterile saline (the Saline 108 
Negative Control Group, n=12), ii) two maternal intramuscular injections of 0.25 mg/kg 109 
betamethasone phosphate + acetate spaced by 24h (the Beta-P+Ac Group, n=12); or iii) two 110 
maternal intramuscular injections of 0.125 mg/kg betamethasone acetate spaced by 24h (the 111 
Beta-Ac Group, n=11).  Fetuses were surgically delivered 48h after treatment initiation and 112 
ventilated for 30 minutes to determine functional lung maturation. Fetuses were euthanized 113 








reaction and western blot assays. Fetal plasma ACTH levels were measured in the cord blood 115 
samples taken at delivery.  116 
Results: Preterm lambs were defined as either ACS treatment responders or non-responders 117 
using an arbitrary cut-off, being a PaCO2 level at 30 minutes of ventilation being more extreme 118 
than two standard deviations from the mean value of the normally-distributed Saline Control 119 
Group values. Relative to Saline Control Group animals, both ACS treatment group animals 120 
showed significantly improved lung physiological responses (blood gas and ventilation data) 121 
and had a biochemical signature (mRNA and surfactant protein assays) consistent with 122 
functional maturation. However, the Beta-Ac Group had a significantly higher treatment 123 
response rate than the Beta-P+Ac Group. These physiological results were strongly correlated 124 
to the amount of surfactant protein A. Birth weight was lower in Beta-P+Ac Group and the 125 
fetal HPA axis was supressed to a greater extent in the Beta-P+Ac Group. 126 
Conclusion: Low dose ACS therapy solely employing Beta-Ac was sufficient for fetal lung 127 
maturation. The elevated materno-fetal betamethasone concentrations associated with the co-128 
administration of betamethasone phosphate did not additionally improve lung maturation, but 129 
were associated with greater HPA axis suppression, a lower ACS treatment response rate, and 130 
lower birth weight – outcomes not desirable in a clinical setting. These data warrant a clinical 131 
investigation of sustained, low-dose ACS treatments that avoid high materno-fetal 132 
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One of the most pressing challenges facing preterm babies (born before 37 weeks’ gestation) 145 
is the transition to breathing room air. As such, perinatal care is significantly focussed on 146 
improving preterm lung function. [1, 2] The introduction of antenatal corticosteroid (ACS) 147 
therapy, subsequent to Liggins and Howie reporting the beneficial effects of ACS in their 148 
landmark 1972 paper, has resulted in an improved prognosis for a large cross-section of preterm 149 
born babies.[3] Today, ACS therapy is standard of care for women at risk of imminent preterm 150 
delivery. The American College of Obstetricians and Gynecologists presently recommends the 151 
use of a single course of ACS for pregnant women between 24 to 33 weeks’ gestation who are 152 
at risk of preterm labor within 7 days. [4] While ACS therapy has been used widely, and 153 
benefits clearly demonstrated when given to the right women at the right time, concerns remain 154 
regarding an increased potential risk of adverse effects, including fetal growth restriction, 155 
neonatal hypoglycaemia, and negative effects on the maternal and fetal hyoithalamus-pituitary-156 
adrenal (HPA) axis. [5-7][8] ACS efficacy per se has also been shown to vary between 157 
individuals in similar environments. Numerous Cochrane reviews of outcomes from a single 158 
course of ACS therapy highlight a reduction in respiratory distress syndrome of approximately 159 
40%.[13]. A similar pattern has been observed in animal studies – both those initially published 160 
by Liggins and in more recent studies by our group, which demonstrate an ACS treatment 161 
efficacy in around 60% preterm sheep administered an accurately timed dose and ventilated 162 
under standard conditions for thirty minutes. [14]. 163 
Despite good evidence that there is room for improvement in ACS treatment efficacy, 164 
reliability, and optimal patient selection, there remains sizable geographic variation in the 165 








that studies to inform a regimen to improve efficacy and durability, whilst minimising the risk 167 
of adverse effects are warranted. 168 
 169 
The present study was undertaken with this objective in mind. We focussed on the differential 170 
pharmacodynamics of betamethasone phosphate (Beta-P) and betamethasone acetate (Beta-171 
Ac) which are commonly used in combination as an ACS therapy. These two agents have 172 
distinct pharmacokinetic profiles after intramuscular injection.[17] Beta-P can be absorbed 173 
quickly after intramuscular administration, which leads to high peak concentration and short 174 
half-life. Beta-Ac slowly dissolves before diffusing into the vascular space. This signature 175 
enables Beta-Ac to have a far longer half-life, with a much lower maximum concentration and 176 
delayed peak concentration time. [18, 19]  177 
 178 
We have previously demonstrated that once a low fetal plasma betamethasone threshold has 179 
been achieved (approximately 1-4ng/mL), further elevations in maternal and fetal plasma 180 
betamethasone concentrations do not additionally benefit fetal lung maturation. [20] We have 181 
also shown that a constant exposure of ≥26 hours is required for lung maturation in preterm 182 
lambs delivered 48h after ACS treatment initiation. [21] Given the evidence showing a bi-183 
phasic glucocorticoid signalling response in key lung maturation determinants (e.g. surfactant 184 
protein A) [22], we hypothesized that the high fetal betamethasone levels achieved by the 185 
betamethasone phosphate component of combined Beta-P and Beta-Ac therapy would be 186 
redundant for driving preterm lung maturation.   187 
To test this hypothesis, we used a preterm sheep model to explore the pharmacodynamic 188 
differences between a single course of combined Beta-P and Beta-Ac used clinically in 189 







[Materials and Methods] 191 
Animal work 192 
All protocols were reviewed and approved by the animal ethics committee of The University 193 
of Western Australia (RA/3/100/1702). All animals used were obtained from a single supplier. 194 
Experiments were performed in the same place and within a two week period during the normal 195 
breeding season. 36 date-mated ewes carrying a singleton fetus were randomized to one of 196 
three groups (n = 12 / each group): i) a Saline Control Group receiving maternal intramuscular 197 
saline injections only; ii) a single course Beta-P + Ac Group receiving two maternal 198 
intramuscular injections of 0.25 mg/kg Beta-P + Ac (Celestone® Chronodose®, Merck Sharp 199 
& Dohme, Australia) spaced by 24 hours on 121 and 122 days’ gestation; or iii) a single course 200 
Beta-Ac Group receiving two  maternal intramuscular injections of 0.125 mg/kg Beta-Ac 201 
(Hovione, Portugal) on  122 and 123 days’ gestation. Each ewe received an intramuscular 202 
injection of 150 mg medroxyprogesterone acetate (Depo-Ralovera; Pfizer, West Ryde, NSW, 203 
Australia) at least five days prior to steroid or control treatments to reduce the risk of steroid-204 
induce preterm labour (term = 150 days). This treatment has been previously shown not to 205 
influence ovine fetal lung maturation. [23] Injectable 3mg/mL solutions of active 206 
pharmaceutical ingredient betamethasone acetate (Hovione, Portugal) were prepared 207 
immediately prior to the study commencing by Oxford Compounding (Perth, Western 208 
Australia) and tested for sterility, potency and the absence of endotoxin contamination. An 209 
overview of the experimental design is provided in Figure 1. In keeping with good ethical 210 
practice, Saline Control Group animals were shared with a separate study and as such received 211 
a total of four maternal intramuscular saline injections. The administration of maternal saline 212 









Delivery and Ventilation 215 
All animals were delivered at 123 or 124 days’ gestation, with all steroid-treated animals 216 
delivered precisely 48h after receiving their first steroid treatment. At delivery, pregnant ewes 217 
received an intravenous injection of midazolam (0.5 mg/kg) and ketamine (10 mg/kg) followed 218 
by a spinal injection of 3mL lidocaine (20 mg/mL). Lambs had a tracheostomy to insert and 219 
secure a 4.5 Fr endotracheal tube. Lambs were then delivered, weighed, dried, and placed on a 220 
temperature-controlled radiant warmer (CosyCot, Fisher & Paykel Healthcare, New Zealand). 221 
Mechanical ventilation was performed using Acutronic Fabian infant ventilators (Acutronic 222 
Medical Systems, Hirzel, Switzerland), with ventilation commencing immediately following 223 
delivery and maintained for 30 minutes, initially with the following parameters: peak 224 
inspiratory pressure (PIP) of 35 cmH2O, positive end-expiratory pressure (PEEP) of 5 cmH2O, 225 
respiratory rate of 50 breaths per minute, inspiratory time of 0.5 seconds, and 100% heated and 226 
humidified oxygen. Tidal volume (Vt) maintained between 7.0 and 8.0 mL/kg by adjustment 227 
of the PIP only, but with maximal PIP limited to 35 cmH2O. An umbilical artery catheter was 228 
placed to allow measurement of arterial blood pH, pO2, pCO2, heart rate, and blood pressure. 229 
Ventilation data including PIP, Vt, and compliance were recorded and the ventilation efficacy 230 
index (VEI), an integrated assessment of ventilation and gas exchange, was calculated as 231 
follows: VEI = 3800/ (respiratory rate [PIP – PEEP] x PaCO2 [mmHg]). [24] Noting a one day 232 
difference in gestational age at delivery between groups , fetal growth curves (y=0.0011x2-233 
0.1557x+5.6144; where x = gestational age and y = delivery weight) generated from Western 234 
Australian merino-cross sheep provided by our livestock supplier and adjusted at our facilities 235 










Necropsy and measurement of static lung compliance 239 
Lambs were euthanized and weighed after 30 minutes ventilation. The chest was opened to 240 
allow measurement of the lung pressure-volume relationship with air inflation of the lung to a 241 
pressure of 40 cmH2O followed by deflation. The volume was standardized by lung weight. 242 
The right lower lobe was dissected free and frozen for molecular analysis.  243 
 244 
Measurement of RNA transcript expression changes in the fetal lung 245 
Messenger ribonucleic acid (mRNA) was extracted from fetal lung tissue (right lower lobe) 246 
using RNeasy Plus Mini kit (QIAGEN, Hilden, Germany) according to the manufacturer’s 247 
instructions. The concentration of extracted mRNA was determined by a broad range nucleic 248 
acid quantitation kit and a Qubit 2.0 Fluorometer (both Life Technologies, Carlsbad, CA). All 249 
mRNA extracts were diluted in nuclease-free water (Life Technologies) to achieve a final 250 
mRNA concentration of 25 ng/μL. 251 
  252 
Quantitative polymerase chain reaction (qPCR) cycling was performed with ovine-specific 253 
TaqMan probe and primer sets (Applied Biosystems, FosterCity, CA) with an OneStep Real-254 
Time PCR System according to the manufacturer’s instructions. The mRNA transcripts for 255 
genes aquaporin 1 (AQP-1), aquaporin 5 (AQP-5), epithelial sodium channel subunit B (ENaC-256 
B), elastin (ELN), nuclear receptor subfamily 3 group c member 1 (NR3C1; also known as the 257 
glucocorticoid receptor, GR), surfactant protein A (SP-A), surfactant protein B (SP-B), 258 
surfactant protein C (SP-C), and surfactant protein D (SP-D) were measured. AQP-1, AQP-5 259 
and ENaC-B expression is associated with improved fluid clearance in lung. A key function of 260 
surfactant proteins (SP-A, SP-B, SP-C and SP-D) is alveolar stabilization and the reduction of 261 








under shear stress. [25, 26] 18s ribosomal protein was used as internal reference to normalize 263 
the amplification data for each gene. Delta quantification cycle values were used to determine 264 
relative expression of transcripts.  265 
 266 
Western Blot 267 
20 mg of fetal lung tissue was added into 400 µL of RIPA Lysis and Extraction Buffer or T-268 
PER Tissue Protein Extraction Reagent (both Thermo Scientific, Waltham, MA) containing 269 
cOmplete™ Protease Inhibitor Cocktail (Roche, Basel, Switzerland) at the ratio of one tablet 270 
per 10 ml of lysis buffer. Samples were prepared in Precellys 2 mL Tissue Homogenizing 271 
Mixed Bead Kit (Bertin Instrumnets, Montigny-le-Bretonneux, France) and were homogenized 272 
at 6500 rpm for 30 seconds using a Precellys 24 Tissue Homogenizer (Bertin Instruments). 273 
Samples were incubated for 90 minutes at 4°C to reduce foaming before they were centrifuged 274 
at 10,000 x rcf for 5 minutes. The supernatant was collected and protein concentrations were 275 
measured by Pierce Rapid Gold BCA Protein Assay Kit (Thermo Scientific).  276 
 277 
Protein in RIPA buffer was used for glucocorticoid receptor (GR) measurements and protein 278 
in T-PER buffer was used for surfactant protein A, B and C (SP-A, SP-B, SP-C) measurements. 279 
An XCell SureLock Mini-Cell Electrophoresis System (Life Sciences) was used for 280 
electrophoresis and transfers. Samples were reduced and 15 µg or 20 µg of protein for 281 
glucocorticoid receptor (GR) assay or SP-A and SP-C, respectively, were applied to each well 282 
in NuPAGE Bis-Tris Mini Gel (Invitrogen). 20 µg of non-reduced samples were used for SP-283 
B assay. NuPAGE 10% Bis-Tris Mini Gels were used. Electrophoresis was run for 50 minutes 284 
at 200 V constant with NuPAGE MOPS SDS Running Buffer (Invitrogen). Protein was 285 








per the manufacturer’s protocol. Membranes were then incubated with No-Stain Protein 287 
Labelling Reagent (Invitrogen) to normalize total protein. Membranes were then incubated 288 
with Blocker FL Fluorescent Blocking Buffer (Thermo Scientific) for 30 minutes followed by 289 
overnight primary antibody incubation at 4°C. Primary antibodies were diluted into 290 
SuperSignal Western Blot Enhancer (Thermo Scientific) as follows: anti-glucocorticoid 291 
receptor antibody (ab225886, abcam, Cambridge, UK) at 1/2,000, anti-surfactant protein 292 
A/PSAP antibody (ab115791, abcam) at 1/1,000, anti-mature surfactant protein B antibody 293 
(WRAB-88912, Seven Hills Bioreagents, OH, kindly provided by Professor Jeffrey 294 
Whitsett,Cincinnati Children’s Hospital, Cincinnati, OH) at 1/5,000 and anti-prosurfactant 295 
protein C antibody (ab40879) at 1/10,000. Washed membranes were incubated with Goat anti-296 
Rabbit IgG (H+L) Highly Cross-Adsorbed Secondary Antibody, Alexa Fluor Plus 800 297 
(Invitrogen) at 1/10,000 in wash buffer (phosphate-buffered saline with 0.05% Tween 20; both 298 
Sigma-Aldrich, St. Louis, MO) for 60 minutes. 299 
 300 
Membranes were analysed using an iBright FL1000 Imaging System (Invitrogen) and target 301 
band concentrations were measured and normalized by total protein concentration. To 302 
normalize the difference between membranes, standard quality control samples were 303 
transferred to each membrane and probed. A concentration-dependent densitometry response 304 
was confirmed with serially diluted lung protein. (Supplemental figure) Thymus extracts were 305 
used as negative control samples to confirm surfactant protein band specificity.   306 
 307 
Correlation and Regression analysis of surfactant protein and physical data 308 
Regression analysis was performed to explore a relationship between surfactant protein 309 








SP-A (protein), SP-B (protein), and SP-C (protein). A simple linear regression model was used 311 
to predict PaCO2 based on V40.   312 
 313 
Hematological analysis from Maternal and Fetal blood 314 
Maternal and fetal umbilical artery cord blood collected at delivery was assayed for plasma 315 
cortisol, adrenocorticotropic hormone (ACTH), and betamethasone concentrations. Cortisol 316 
and ACTH level were measured by an independent clinical pathology laboratory (Vetpath, 317 
Perth, Australia). The detection limit was 5.5 nmol/L for cortisol levels and 5 pg/mL for ACTH 318 
levels. For the purposes of statistical analyses, we assumed a 5 pg/mL ACTH level for samples 319 
which were found to be below the limit of detection. Betamethasone concentrations were 320 
measured with mass spectrometry as described previously. [14, 20] 321 
 322 
Definition of antenatal corticosteroid response  323 
We defined animals as either ACS treatment responders or non-responders as described 324 
previously. [13, 14]  Briefly, we used normally distributed Saline Control Group data and set 325 
an arbitrary cut-off, based on cord arterial PaCO2 levels after 30 minutes of ventilation. Those 326 
animals considered to have responded to treatment (responder subgroup) were defined as 327 
having a PaCO2 level more extreme than 2 standard deviations (SD) below the mean value of 328 
the Saline Control Group’s PaCO2 value. Animals were defined as being ACS treatment non-329 
responders (non-responder subgroup) when having a 30-minute ventilation PaCO2 within 2 330 










Statistical analysis 334 
Statistical analysis was performed using IBM SPSS Statistics for Windows, version 25.0 (IBM 335 
Corp, Armonk, NY). One-way analysis of variance (ANOVA) followed by Tukey’s or Games-336 
Howell’s post-hoc tests was used for multiple group comparisons as appropriate. 337 
Hematological data in ACS-treated groups were tested for significance with t-tests or Mann-338 
Whitney U tests. A chi-square test was used for comparing of rate of ACS responsiveness 339 























One animal from the Beta-Ac Group delivered before the protocol commenced (prior to steroid 356 
treatment) and was removed from further analyses. All animals from the Saline Control Group 357 
and the Beta-P+Ac Group were delivered at 123 days’ gestation and all of the Beta-Ac Group 358 
animals were at 124 day’s gestation. There were no significant inter-group differences in sex, 359 
cord blood pH, cord blood PaCO2, or lung weight per body weight. While there was no 360 
significant difference in birth weight between the Saline Control Group and the Beta-Ac Group 361 
animals, Beta-P+Ac animals has significantly lower birth weights than the Saline Control 362 
Group animals (Table 1, Figure 2). The statistically significant difference in birth weight we 363 
identified was maintained when the one-day difference in gestational age was controlled for by 364 
adjustment with the fetal growth curve. Additionally, there were no differences in birth weight 365 
between genders in each treated group (data not shown).  366 
 367 
Ventilation Data (30 minutes) 368 
Arterial blood gas measurements and key physiological parameters after 30 minutes of 369 
ventilation are shown in Figure 2. Both ACS treatment groups had significantly improved pH 370 
and PaCO2 compared with the Saline Control Group. Only the Beta-Ac Group had a PaO2 value 371 
significantly higher than that of the Saline Control Group. Heart rate was significantly lower 372 
in both the Beta-P+Ac and Beta-Ac Group relative to the Saline Control Group, but there were 373 
no significant differences in mean blood pressure between groups.  374 
Based on a Saline Control Group PaCO2 mean and a standard division after 30 minutes 375 
ventilation (117.8±20.8 mmHg, respectively), we set an arbitrary cut-off for determining ACS 376 
responder and non-responder animals at 76.1 mmHg. Accordingly, 33.3 % (n = 4/12) of 377 








9/11) of animals in the Beta-Ac Group (Figure 3). The responder rate was significantly higher 379 
in the Beta-Ac Group relative to the Beta-P+Ac Group (p = 0.036). There were no animals 380 
from the Saline Control Group assigned to the responder subgroup. 381 
 382 
Ventilation data collected 30 minutes into the procedure are presented in Figure 4. There were 383 
no differences in PIP between the ACS-treated groups. Both the Beta-P+Ac and Beta-Ac Group 384 
showed significantly higher dynamic compliance, Vt, and VEI compared with the Saline 385 
Control Group. There were no differences in those parameters between the Beta-P+Ac and 386 
Beta-Ac Group. Figure 5 shows static lung compliance during necropsy. As it showed in 387 
ventilation data, lung gas volume at 40 mmH2O was significantly higher in the Beta-P+Ac and 388 
Beta-Ac Group than the Saline Control Group. PV curve showed both treatment groups had 389 
larger volume loops than the Saline Control Group. 390 
 391 
Quantitative polymerase chain reaction (qPCR) analysis of transcript expression change in 392 
the fetal lung 393 
AQP-1 and AQP-5 mRNA transcripts were significantly elevated in the Beta-P+Ac Group 394 
compared to the Saline Control Group. There were no significant differences in these values 395 
between the Beta-Ac and Saline Control Group (Table 2). Both steroid treatment groups had 396 
significant increases in transcripts for ENaC-B, SP-A, SP-B, SP-C and ELN compared to the 397 
Saline Control Group. The Beta-P+Ac Group showed higher fold change in ENaC-B than the 398 
Beta-Ac. GR transcript levels were significantly lower in the Beta-Ac Group relative to both 399 
the Saline Control and Beta-P+Ac Groups. There was no significant difference in GR transcript 400 









Western Blot analysis of lung tissue 403 
GR, SP-A, mature SP-B and pro SP-C bands were confirmed at 90 kDa, 35-37 kDa, 18 kDa, 404 
and 19 kDa, respectively (Supplemental figure). Band volumes were determined to be 405 
proportional to total protein concentration. SP-A is highly heterogenous on immunoblotting 406 
analyses due to the presence of multiple glycosylation and acetylation sites and multimeric 407 
forms resistant to reduction. [27] In the present analysis, SP-A was detected in separate bands 408 
at 35 kDa and 37 kDa. We recognized both bands as SP-A-specific due to their absence in 409 
protein extracts from ovine thymus, which does not express SP-A at discernible levels. [28] As 410 
the 37 kDa SP-A band volume was unaffected by ACS, we have only reported band volumes 411 
for the 35 kDa SP-A form in this paper. SP-B showed two bands at 18 kDa and 25kDa. As the 412 
band at 18 kDa is a homodimer of mature SP-B and the band at 25 kDa is likely proSP-B, only 413 
mature SP-B was analyzed. [29]  414 
 GR protein concentration was significantly lower in the Beta-P+Ac Group compared with the 415 
Saline Control Group. There was no difference between the Saline Control Group and the Beta-416 
Ac Group (Table 2). Both the Beta-P+Ac Group and the Beta-Ac Group showed significantly 417 
high SP-A and pro SP-C concentrations compared to the Control Group. There were no 418 
differences between the Beta-P+Ac Group and Beta-Ac Group for GR, SP-A or pro SP-C 419 
concentrations. Only the Beta-P+Ac Group showed significant higher SP-B concentrations 420 
than the Saline Control Group. 421 
 422 
Regression analysis of surfactant protein and physical data 423 
Figure 6A and 6B shows the predicted correlations between SP-A (protein) concentration and 424 
V40, and between V40 and 30-minute cord arterial blood PaCO2 values. While SP-A (protein) 425 








0.23, p<0.05), SP-C (protein) was not (β = 0.04, p=0.72) (R2 = 0.734). V40 was a significant 427 
predictor of PaCO2 (β = -0.82, p<0.001, R
2 = 0.683). (Figure 6C). A single regression analysis 428 
was calculated to predict V40 based on SP-A (protein). It showed that SP-A (protein) was 429 
significant predictor of V40 (β = 0.84, p<0.001, R2 = 0.719). (Figure 6A). 430 
 431 
Hematological analyses of Maternal and Fetal blood 432 
Maternal and fetal plasma levels of cortisol and ACTH were measured with maternal blood 433 
and umbilical cord blood collected at delivery. Cortisol levels were below the limit of detection  434 
(5.5 nmol/L) in all but three maternal blood samples from the Beta-Ac Group (16.7, 23.2, 80 435 
nmol/L) and one fetal blood sample from the Beta-Ac Group (11 nmol/L); accordingly, group 436 
differences in cortisol levels were not analysed. Plasma ACTH levels are shown in Figure 7A. 437 
ACTH levels in two maternal samples and one fetal sample from the Beta-P+Ac Group, and 438 
one maternal sample from the Beta-Ac Group were below the limit of detection at 5 pg/mL. 439 
We arbitrarily replaced them with a value of 5 pg/mL to allow analysis as outlined above. No 440 
difference was seen in maternal ACTH values between the Beta-P+Ac and Beta-Ac Group. 441 
Fetal plasma ACTH levels were significantly lower in the Beta-P+Ac Group than the Beta-Ac 442 
Group. Figure 7B shows betamethasone concentrations in maternal and fetal plasma at delivery. 443 
Maternal betamethasone concentrations were six times lower and fetal concentrations three 444 













Principal findings 451 
The primary findings of this study are: i) that a single course (two doses at 0.125 mg/kg) of 452 
betamethasone acetate achieved more consistent functional maturation of the ovine preterm 453 
lung compared to that achieved when betamethasone acetate was administered in combination 454 
with betamethasone phosphate as two 0.25mg/kg doses; and ii) that relative to the use of 455 
betamethasone acetate alone, a single course of combined betamethasone phosphate and 456 
acetate resulted in higher maternal and fetal plasma betamethasone concentrations in 457 
association with a greater degree of fetal HPA axis suppression and statistically significant 458 
reductions in birth weight. On the basis of these observations, it may be concluded that for 459 
deliveries occurring 48h after treatment initiation, not only does the co-administration of 460 
betamethasone phosphate with acetate fail to additionally benefit fetal ovine lung maturation, 461 
it may in fact suppress GR-driven maturational signalling in the lung, relative to that elicited 462 
by the sole administration of betamethasone acetate at a lower total dose. Based on the 463 
pharmacokinetics and mode of action of the agents used, the root cause of these differences in 464 
treatment outcomes is likely the elevated materno-fetal betamethasone concentrations derived 465 
from the use of betamethasone phosphate. Additional studies with a specific focus on molecular 466 
mechanisms of GR signalling are necessary to validate this theory.  467 
 468 
Overall, both treated groups had improved lung maturation compared to the Saline Control 469 
Group. Favourable arterial blood gas data (pH, PaO2, and PaCO2), ventilation data (dynamic 470 
compliance, Vt, and VEI) and static compliance (V40 and pressure-volume curves) data all 471 
demonstrate that both ACS regimens could mature the preterm lung structurally, leading to 472 








suggesting that both ACS therapies could stabilize the cardiovascular system, potentially by 474 
improving cardiac performance and reducing vascular permeability. Evidence for preterm lung 475 
maturation independent of betamethasone phosphate use is also provided by our mRNA 476 
transcript analyses. In the present study, both ACS-treatment groups showed significantly 477 
increased mRNA transcript for ENaC-B, SP-A, SP-B, SP-C, and ELN relative to Saline Control 478 
Group animals. However, there were no differences in these mRNA transcripts apart from 479 
ENaC-B and GR between ACS-treatment groups. Although there were no significant 480 
differences, these values seem to be correlated with the total amount of ACS administered, as 481 
shown in the case of ENaC-B. Other than for SP-B, these differences in mRNA expression did 482 
not equate to increased protein expression.    483 
 484 
Although the changes in PaCO2 values between the ACS-treatment groups were not 485 
significantly different, when animals were classified into ACS responders and non-responders 486 
on the basis of an arbitrary cut-off, derived from Saline Control Group values there was a clear 487 
difference in the inter-animal variability of the two steroid regimens.  It is important to note 488 
that PaCO2 levels were used instead of PaO2 levels (which were significantly different between 489 
ACS-treatment groups) due to the potential for PaO2 values to be confounded by alterations in 490 
the patency of the ductus arteriosus. [14, 30] Although not directly comparable with a clinical 491 
outcome such as respiratory distress syndrome, it is interesting to note that a significant degree 492 
of ACS non-responsiveness is regularly reported in human randomised control trials of ACS 493 
therapy, even when other variables (i.e. successful administration of treatment course, delivery 494 
within 7d of treatment, etc) are controlled for. It would be of significant interest, and great 495 
potential importance, to determine if a constant, low-concentration materno-fetal ACS 496 








similarly reduced the variability of treatment efficacy, yielding more favourable number 498 
needed to treat values for outcomes including perinatal death and respiratory distress syndrome.  499 
 500 
In seeking to explore the basis for the difference in ACS outcomes identified in this study, it is 501 
important to explore the pharmacokinetics and pharmacodynamics of betamethasone acetate 502 
and betamethasone phosphate. It is well known from both animal and human studies that 503 
adverse ACS effects have a clear dose-dependent risk profile, including for risks of fetal growth 504 
restriction, impairment of HPA axis function, and neurodevelopmental effects. [31-34] Given 505 
that lower materno-fetal steroid exposures are desirable, it is remarkable that the Beta-Ac 506 
Group, which received a much lower dose of glucocorticoids had lung maturation that was at 507 
least as good as that seen in the higher dose Beta-P+Ac Group. Although data are limited to 508 
effects within 48 hours of ACS treatment, it is apparent that the lower dose ACS caused less 509 
disruption to fetal growth and the HPA axis. 510 
 511 
Dissecting the differences in the Beta-P+Ac and Beta-Ac treatment protocols that contribute to 512 
the difference in treatment effects and observed adverse outcomes in this study is of particular 513 
importance. It is important to note that the Beta-P+Ac Group not only received a much larger 514 
total dose of betamethasone, but also that this treatment conveyed a substantially higher 515 
materno-fetal plasma betamethasone concentration. Due to its high solubility, the phosphate 516 
ester of betamethasone generates a higher peak concentration (around 5 times that of Beta-Ac 517 
alone in the sheep) that is rapidly cleared. [19] Our previous results have shown that a sustained, 518 
low-magnitude betamethasone exposure is far more effective in maturing the preterm ovine 519 









Clinical implications 522 
This work has two important implications for clinical ACS use. The first relates to efforts to 523 
improve the safety and efficacy of combined betamethasone acetate and betamethasone 524 
phosphate therapy based on the protocol used by Liggins and Howie in their landmark clinical 525 
trial that is now widely employed in the United States, Australia and parts of Europe.[3] The 526 
benefits of combined therapy, when administered to the right women at the right time, are 527 
clearly supported by multiple randomised control trials.[13]  However, these same data also 528 
make it clear that treatment responsiveness is extremely variable, and a number of additional 529 
studies have reported an increased risk of harm in association with betamethasone acetate and 530 
betamethasone phosphate use. [6-10] The treatment variability and ACS dose-dependent 531 
reduction in birth weight seen clinically in association with combined betamethasone acetate 532 
and phosphate use was also identified in the present study. Given that the exclusive use of 533 
betamethasone acetate reduced HPA axis disruption, lessened effects on fetal growth, and 534 
improved overall treatment success rate, it is reasonable to suggest that clinical studies to 535 
explore use of a betamethasone acetate-only therapy (or therapy with another glucocorticoid 536 
so delivered to replicate the constant, low-amplitude exposure given by betamethasone acetate 537 
dosing) are now justified. On the other hand, variable responsiveness to ACS treatment per se 538 
has not been fully understood. Once we have a better understanding of the critical mechanisms 539 
driving steroid-induced lung maturation there may be a chance to identify those likely not to 540 
respond early in pregnancy. We may also be able to tailor therapies to take these (likely) genetic 541 
differences into account.  542 
 543 
Secondly, this work also has implications for ACS dosing regimens based around the sole use 544 







employed WHO-recommended protocol).[36] Whether administering two  12 mg doses of 546 
betamethasone phosphate every 24h, or four 6 mg doses of dexamethasone phosphate every 12 547 
hours, these two protocols each generate a pulsatile pattern of exogenous glucocorticoid 548 
exposure, characterised by comparatively high concentration peaks (notably in the 12mg 549 
betamethasone phosphate protocol) immediately after administration, rapidly followed by 550 
concentration troughs immediately prior to the subsequent administration. Our earlier work has 551 
demonstrated the importance of a constant steroid exposure and that the concentration 552 
threshold for an efficacious threshold is comparably low, around 1-4 ng betamethasone per mL 553 
of fetal plasma, and certainly much lower than the concentration peaks generated by 554 
contemporary dexamethasone and betamethasone phosphate concentrations. [19, 35] Based on 555 
these findings, and the new data presented herein, we suggest that a betamethasone or 556 
dexamethasone regimen based on frequent, lower-dose treatments (perhaps as low as 0.05 557 
mg/kg) may constitute an efficacious ACS treatment regimen absent of the high concentration 558 
peaks that we have shown to be both redundant for fetal lung maturation, and potentially 559 
causative of harm. 560 
 561 
Research implications 562 
Unpacking the molecular mechanisms driving the differential treatment effects identified in the 563 
present study will be of particular importance to the future optimisation of this important 564 
therapy. A particular focus will likely be on why a higher materno-fetal steroid exposure 565 
correlates with increased variability in treatment efficacy. The regulation of surfactant protein 566 
A provides some insight into one explanation for this phenomenon. Although not essential for 567 
lung function, SP-A is implicated in tubular myelin formation, in the formation of surfactant 568 








or SP-C showed a strong correlation with V40 which represented static lung compliance. 570 
(Figure 6A) While both SP-A and SP-B have been shown to be essential for normal lung 571 
function, SP-A protein expression is likely quite informative in assessing ACS treatment 572 
response and lung maturation status.V40 was also correlated to PaCO2 at 30 minutes ventilation. 573 
(Figure 6B) 574 
 575 
Ballard and colleagues have previously demonstrated that SP-A is exquisitely responsive to 576 
GR-stimulation. Unlike other surfactant proteins, such as SP-B, that appear to exhibit a linear 577 
response to GR-activation, SP-A appears to have a pronounced bi-phasic response, wherein 578 
maximal transcript expression occurs at a low exogenous steroid concentration, and is then 579 
reduced (apparently via both negative feedback and increased mRNA turnover) at higher 580 
steroid concentrations. [22]  Bridges and colleagues have recently demonstrated the role of GR 581 
activation in the modulation of WNT, JAK-STAT and VEGF signalling in the fetal lung, 582 
leading to matrix fibroblast differentiation and mature alveolar type I and II cell transformation. 583 
[40] It is tempting to speculate that, similar to the situation observed with SP-A responses, one 584 
or more key regulatory elements in these pathways has a ‘goldilocks’ response to GR signalling, 585 
where too little (in terms of both magnitude and/or duration) or too much exposure results in a 586 
sub-optimal maturation response.     587 
 588 
Strengths and limitations 589 
A number of limitations should be taken into account when assessing the translatability of the 590 
data presented herein. Although the sheep is an excellent translational model to study ACS 591 
therapy, it should be remembered that the data are from an animal rather than a human clinical 592 








number of animals. The study was adequately powered to explore a potential difference 594 
between ACS treatments and saline control, but was not designed to assess any (likely more 595 
subtle) differences between ACS-treatment groups. It is possible that a much larger study 596 
(group sizes of ~30) may allow for identification of treatment differences between ACS-groups, 597 
and also assist in the identification of any statistically significant difference in delivery weight 598 
between the Beta-Ac Group and the Saline Control Group.  599 
 600 
There were two limitations of study design; as appropriate for good ethical practice and the 601 
reduction of animals used in research studies, the Saline Control Group animals were shared 602 
with a separate protocol and received four maternal saline injections on different days from the 603 
animals treated with ACS. Based on a comparison with earlier data (not shown), an additional 604 
two injections of saline do not alter fetal lung development.  Secondly, there was a one-day 605 
difference in gestational age between the Beta-Ac group animals and the Saline Control / Beta-606 
P+Ac Group animals due to limitations in our sheep mating capacity. To ensure the observed 607 
difference in birthweight was not confounded by this difference, we corrected for one day of 608 
growth using fetal weight charts previously developed by our group. In performing a correction, 609 
we found that the observed difference in weights retained statistical significance. Given this, 610 
and the strong body of evidence linking a dose-dependent relationship between fetal 611 
glucocorticoid exposure and growth restriction, we are confident that the observed difference 612 
is a function of the treatment received, rather than a small difference in gestational age. 613 
 614 
Conclusion 615 
We hypothesised that the high fetal betamethasone levels achieved by the betamethasone 616 








preterm lung maturation. The results of this study support this hypothesis, and also strongly 618 
suggest that lower-dose treatment with Beta-Ac, avoiding high materno-fetal steroid exposures, 619 
is both safer and more effective than combined Beta-P and Beta-Ac therapy. These findings 620 
add further impetus to the undertaking of clinical trials to optimise the agent choice and dosing 621 
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Table 1 738 
Summary of delivery data. 739 
 740 
Table 1 741 
  Control  Beta-P+Ac Beta-Ac 
n 12 12 11 
Gestational Age (d)  123 123 124 
Birth Weight (kg) 2.8±0.3 2.4±0.3* 2.7±0.3 
Sex (M/F) 5/7 8/4 6/5 
Cord pH 7.33±0.15 7.36±0.15 7.37±0.15 
Cord blood PaCO2 
(mmHg) 
53.1±4.8 48.4±4.2 46.8±4.5 
Lung Weight (g/kg) 35.6±3.8 34.3±3.7 33.3±3.2 
*: significantly lower than the Control Group (p<0.01) 742 
 743 
Table 2 744 
Lung messenger RNA and protein quantification in fold change relative to control animals  745 
 746 








  Fold change (vs Control) 
Tissue Target 
mRNA 
Control Beta-P+Ac Beta-Ac 
Lung AQP-1 1.00 (0.81-1.24) 1.40 (1.11-1.78)* 1.13 (0.89-1.44) 
AQP-5 1.00 (0.72-1.39) 1.76 (1.27-2.45)* 1.35 (0.96-1.88) 
ENaC-B 1.00 (0.73-1.37) 2.34 (1.77-3.10)* 1.50 (1.13-2.00)*† 
ELN 1.00 (0.84-1.20) 2.45 (1.87-3.21)* 2.08 (1.46-2.95)* 
GR 1.00 (0.84-1.19) 0.90 (0.73-1.11) 0.70 (0.57-0.87)* † 
SP-A 1.00 (0.57-1.75) 2.63 (1.58-4.37)* 2.12 (1.26-3.57)* 
SP-B 1.00 (0.71-1.40) 1.82 (1.32-2.50)* 1.47 (1.06-2.04)* 
SP-C 1.00 (0.69-1.45) 2.25 (1.52-3.34)* 1.92 (1.28-2.87)* 
SP-D 1.00 (0.65-1.45) 1.27 (0.72-2.23) 0.78 (0.44-1.39) 
Tissue Target 
Protein 
Control Beta-P+Ac Beta-Ac 
Lung GR 1.00 (0.79-1.21) 0.54 (0.31-0.76) * 0.73 (0.48-0.97) 
 SP-A 1.00 (0.78-1.22) 1.85 (1.37-2.32) * 2.43 (1.93-2.94) * 
 SP-B 1.00 (0.52-1.47) 2.33 (1.52-3.12) * 1.73 (1.03-2.43) 
 SP-C 1.00 (0.70-1.30) 1.88 (1.36-2.39) * 1.99 (1.55-2.44) * 
Average (95% Confidence Interval) 748 
*: significant difference compared to the Control Group (p<0.05) 749 








[FIGURE LEGENDS] 751 
Figure 1. Timing of interventions in each group 752 
i) Saline Control Group animals received four maternal intramuscular injections of 2 ml of 753 
saline at 115, 116, 117 and 118 days’ gestation. Fetuses were delivered at 123 days gestational 754 
age. ii) Beta-P+Ac Group animals received two maternal intramuscular injections of 0.25 755 
mg/kg of Beta-P+Ac at 121 and 122 days’ gestation. Fetuses were delivered at 123 days 756 
gestational age, 48 hours after commencement of intervention. iii) Beta-Ac Group animals 757 
received two maternal intramuscular injections of 0.125 mg/kg of Beta-Ac at 122 and 123 days’ 758 
gestational age. Fetuses were delivered at 124 days gestational age, 48 hours after 759 
commencement of intervention. IM: intramuscular injection, GD: gestational day. 760 
 761 
Figure 2.  Birth weight, blood gas measurement and physiological parameters 762 
Birth weight, arterial blood gas measurements and physiological parameters at 30 minutes of 763 
preterm lamb ventilation. A, birth weight (Saline Control vs Beta-P+Ac, mean difference -0.43 764 
[p=0.007, 95%  CI: -0.75 to -0.11], Saline Control vs Beta-Ac, mean difference -0.13 [p=0.619, 765 
95%  CI: -0.46 to 0.20], Beta-P+Ac vs Beta-Ac, mean difference 0.30 [p=0.078, 95%  CI: -766 
0.03 to 0.63]) B, pH (Saline Control vs Beta-P+Ac, mean difference 0.26 [p<0.001, 95%  CI: 767 
0.14 to 0.38], Saline Control vs Beta-Ac, mean difference 0.33 [p<0.001, 95%  CI: 0.22 to 768 
0.44], Beta-P+Ac vs Beta-Ac, mean difference 0.07 [p=0.420, 95%  CI: -0.07 to 0.21]) C, 769 
PaCO2 (Saline Control vs Beta-P+Ac, mean difference -35.8 [p=0.001, 95%  CI: -57.3 to -770 
14.3], Saline Control vs Beta-Ac, mean difference -54.0 [p<0.001, 95%  CI: -76.0 to -32.0], 771 
Beta-P+Ac vs Beta-Ac, mean difference -18.2 [p=0.119, 95%  CI: -40.2 to 3.8]), D, pO2 (Saline 772 
Control vs Beta-P+Ac, mean difference 36.3 [p=0.057, 95%  CI: -1.0 to 73.5], Saline Control 773 








mean difference 81.6 [p=0.100, 95%  CI: -14.2 to 177.4]), E, HR (Saline Control vs Beta-P+Ac, 775 
mean difference -52.2 [p<0.001, 95%  CI: -78.8 to -25.5], Saline Control vs Beta-Ac, mean 776 
difference -31.5[p=0.021, 95%  CI: -58.8 to -4.3], Beta-P+Ac vs Beta-Ac, mean difference 20.6 777 
[p=0.167, 95%  CI: -6.6 to 47.9]), F, mBP (no differences). Asterisk indicates significant 778 
difference between groups. Error bars represent ±1 standard deviation. CI: Confidence Interval. 779 
 780 
Figure 3. Response rate to ACS treatment 781 
Preterm lambs were divided into a responder group or non-responder group based on an 782 
arbitrary cut-off. The cut-off was set at 76.1 mmHg in PaCO2 at 30 minutes ventilation, which 783 
was 2 standard deviations below of PaCO2 average in the Control Group at 30 minutes 784 
ventilation.  A, all animals PaCO2 at 30 minutes ventilation data were plotted. The dashed line 785 
shows the arbitrary cut-off at 76.1 mmHg. The animals under the dashed line were assigned to 786 
the responder group. Animals above the line were assigned to the non-responder group. B, 787 
Graph shows the response rate in both ACS treated group. *The Beta-Ac Group showed a 788 
significantly higher response rate at 81.8 % than the Beta-P+Ac Group at 33.3 %. (χ2 (1)=3.69, 789 
p=0.036).   790 
 791 
Figure 4. Ventilation data 792 
Ventilation data at 30 minutes. A, PIP (Saline Control vs Beta-P+Ac, mean difference -1.66 793 
[p=0.163, 95% CI: -3.94 to 0.60], Saline Control vs Beta-Ac, mean difference -0.81 [p=0.087, 794 
95% CI: -1.73 to 0.11], Beta-P+Ac vs Beta-Ac, mean difference 0.86 [p=0.620, 95% CI: -1.50 795 
to 3.21]) B, dynamic compliance (Saline Control vs Beta-P+Ac, mean difference 0.22 [p=0.012, 796 
95% CI: 0.05 to 0.39], Saline Control vs Beta-Ac, mean difference 0.30 [p<0.001, 95% CI: 797 








C, Vt (Saline Control vs Beta-P+Ac, mean difference 2.78 [p<0.001, 95% CI: 1.68 to 3.87], 799 
Saline Control vs Beta-Ac, mean difference 3.40 [p<0.001, 95% CI: 2.46 to 4.35], Beta-P+Ac 800 
vs Beta-Ac, mean difference 0.63 [p=0.463, 95% CI: -0.69 to 1.94]) D, VEI (Saline Control vs 801 
Beta-P+Ac, mean difference 0.016 [p=0.045, 95% CI: 0.0003 to 0.0312], Saline Control vs 802 
Beta-Ac, mean difference 0.022 [p=0.004, 95% CI: 0.008 to 0.036], Beta-P+Ac vs Beta-Ac, 803 
mean difference 0.006 [p=0.680, 95% CI: -0.013 to 0.026]) Asterisk indicates significant 804 
difference between groups. Error bars represent ±1 standard deviation. CI: Confidence 805 
Interval; PIP, peak inspiratory pressure; VEI, ventilation efficiency index; Vt, tidal volume. 806 
 807 
Figure 5. Lung maturation analysis. 808 
A, Static lung gas volumes measured at a maximal pressure of 40 cmH2O. (Saline Control vs 809 
Beta-P+Ac, mean difference 726 [p=0.001, 95% CI: 358 to 1092], Saline Control vs Beta-Ac, 810 
mean difference 1103 [p<0.001, 95% CI: 805 to 1401], Beta-P+Ac vs Beta-Ac, mean 811 
difference 377 [p=0.095, 95% CI: -56 to 812]) B, Pressure-volume relationship for air inflation 812 
and deflation of the lung at necropsy. The higher line from 0 cmH2O to 40 cmH2O of pressure 813 
in each loop is the inflation arm and the lower line from 40 cmH2O to 0 cmH2O of pressure is 814 
the deflation arm. Asterisk indicates significant difference between groups. Error bars represent 815 
±1 standard deviation. CI: Confidence Interval. 816 
 817 
Figure 6. Relationship between surfactant protein and lung physical maturation. 818 
A, Graphs show correlations between protein amount of SP-A and V40 as static lung 819 
compliance. Each group was plotted with different colour. B, Graph shows correlation between 820 
V40 and PaCO2 at 30 minutes ventilation. Each group was plotted with different colour. C, 821 








observed variables were presented by square box and latent or unmeasured variables were 823 
presented by circle. A number along with each arrow is the standardized partial regression 824 
coefficient.   825 
 826 
Figure 7. Hematological results from Maternal and Fetal blood 827 
ACTH and betamethasone concentrations in maternal and fetal plasma at delivery A, maternal 828 
or fetal plasma ACTH levels. Three samples (two in the Beta-P+Ac Group and one in the Beta-829 
Ac Group) from maternal plasma and one sample from fetal plasma in the Beta-P+Ac Group 830 
showed too low ACTH level to be detected. Maternal ACTH (no difference, p=0.104, Mann-831 
Whitney U test), fetal ACTH (Significant difference, p=0.002, Mann-Whitney U test). B, 832 
maternal or fetal betamethasone concentration at delivery. Maternal betamethasone 833 
concentration (Beta-P+Ac vs Beta-Ac, mean difference -5.73 [p<0.001, 95% CI: -7.63 to 3.83], 834 
t-test), fetal betamethasone concentration (significant difference, p<0.001, Mann-Whitney U 835 
test). Parenthesis indicates the number of samples which could not detect ACTH. Asterisk 836 
indicates significant difference between groups. Error bars represent ±1 standard deviation. CI: 837 
Confidence Interval. 838 
 839 
Supplemental Figure. Images of correlations between target bands and total protein 840 
amount in western blot analysis. 841 
Serially diluted lung proteins every 5 µg from 5 µg to 25 µg were analysed with GR, SP-A, 842 
SP-B, and pro SP-C antibody. Thymus was also used as a negative control for SP-A, SP-B, and 843 
pro SP-C antibody. Blue bands show total protein and target bands are shown as green bands 844 
at arrows or a square bracket. Gray scale bands show target bands. Band volume of both total 845 
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